InsiderTrades

Form 4 for GILD Gilead Sciences

Accepted 2026-03-12 00:00:00 ET · period of report 2026-03-10 · accession 0001638643-26-000014 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-03-12 2026-03-10 GILD O'Day Daniel Patrick COB, CEO, Dir M - OptEx — +20.0K 662.3K +3% —
D 2026-03-12 2026-03-10 GILD O'Day Daniel Patrick COB, CEO, Dir F - Tax $148.56 -9,767 652.6K -1% -$1.45M
DM 2026-03-12 2026-03-10 GILD O'Day Daniel Patrick COB, CEO, Dir A - Grant $0.00 +155.6K 122.8K New $0
D 2026-03-12 2026-03-10 GILD O'Day Daniel Patrick COB, CEO, Dir M - OptEx — -20.0K 68.0K -23% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-10 M A 20,026 — 662,334 D — — (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
2 Common Common Stock 2026-03-10 F D 9,767 $148.56 652,567 D — —
3 Derivative Restricted Stock Unit 2026-03-10 A A 32,815 — 100,859 D — · — to — 32,815 Common Stock (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
4 Derivative Non-qualified Stock Option (Right to Buy) 2026-03-10 A A 122,755 $0.00 122,755 D $148.56 · — to 2036-03-10 122,755 Common Stock (F3) The stock options have a four-year vesting schedule. 25% of the options vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
5 Derivative Restricted Stock Unit 2026-03-10 M D 20,026 — 68,044 D — · — to — 20,026 Common Stock (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.